Literature DB >> 11282510

Antibodies and Plasmodium falciparum merozoites.

R Ramasamy1, M Ramasamy, S Yasawardena.   

Abstract

There is considerable interest in using merozoite proteins in a vaccine against falciparum malaria. Observations that antibodies to merozoite surface proteins block invasion are a basis for optimism. This article draws attention to important and varied aspects of how antibodies to Plasmodium falciparum merozoites affect red blood cell invasion.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11282510     DOI： 10.1016/s1471-4922(00)01946-2

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN： 1471-4922


  8 in total

1.  Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.

Authors:  Asma Abdullah Nurul; Mohd Nor Norazmi
Journal:  Parasitol Res       Date:  2010-11-06       Impact factor: 2.289

2.  Determination of antigenic domain in GST fused major surface protein (Nc-p43) of Neospora caninum.

Authors:  E S Son; H J Ahn; J H Kim; D Y Kim; H W Nam
Journal:  Korean J Parasitol       Date:  2001-09       Impact factor: 1.341

3.  Low multiplication rates of African Plasmodium falciparum isolates and lack of association of multiplication rate and red blood cell selectivity with malaria virulence.

Authors:  Anne-Marie Deans; Kirsten E Lyke; Mahamadou A Thera; Christopher V Plowe; Abdoulaye Koné; Ogobara K Doumbo; Oscar Kai; Kevin Marsh; Margaret J Mackinnon; Ahmed Raza; J Alexandra Rowe
Journal:  Am J Trop Med Hyg       Date:  2006-04       Impact factor: 2.345

4.  Top-down or bottom-up regulation of intra-host blood-stage malaria: do malaria parasites most resemble the dynamics of prey or predator?

Authors:  Daniel T Haydon; Louise Matthews; Rebecca Timms; Nick Colegrave
Journal:  Proc Biol Sci       Date:  2003-02-07       Impact factor: 5.349

5.  Suppressive and additive effects in protection mediated by combinations of monoclonal antibodies specific for merozoite surface protein 1 of Plasmodium yoelii.

Authors:  Irosoki Eslava; Gilberto Payares; Beatriz M Pernia; Anthony A Holder; Lilian M Spencer
Journal:  Malar J       Date:  2010-02-10       Impact factor: 2.979

6.  The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum.

Authors:  Zbynek Bozdech; Manuel Llinás; Brian Lee Pulliam; Edith D Wong; Jingchun Zhu; Joseph L DeRisi
Journal:  PLoS Biol       Date:  2003-08-18       Impact factor: 8.029

7.  Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chimeric protein formulated in montanide ISA 720 in healthy adults.

Authors:  Jinhong Hu; Zhihui Chen; Jun Gu; Mobin Wan; Qian Shen; Marie-Paule Kieny; Jia He; Zhen Li; Qingfeng Zhang; Zarifah Hussain Reed; Yongmei Zhu; Wenjie Li; Yang Cao; Li Qu; Zhifang Cao; Qiang Wang; Haitao Liu; Xuegong Pan; Xiudong Huang; Dongmei Zhang; Xiangyang Xue; Weiqing Pan
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

8.  Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations.

Authors:  R Ramasamy; S Yasawardena; A Zomer; G Venema; J Kok; K Leenhouts
Journal:  Vaccine       Date:  2006-03-02       Impact factor: 3.641
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.